Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||MK2206 + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MK2206||MK-2206||Akt Inhibitor (Pan) 18||MK2206 binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation (PMID: 20571069).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MK2206 + Paclitaxel||Phase Ib/II||Actionable||In a Phase Ib clinical trial, the combination of MK2206 and Taxol (paclitaxel) was well tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors, with partial response in 24% (5/21) and stable disease in 43% (9/21) of patients (PMID: 25688104)||25688104|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|